// App-Quantinova.ai

P254 : Secukinumab provides rapid and sustained improvement in joint tenderness and swelling in patients with PsA: 2-year results from the Phase 3 FUTURE 5 study

Researchers

Presenter

  • Iain McInnes

Principal Investigators

  • Hector Chinoy

  • Darren Asquith

  • Abigail White

  • Corine Gaillez

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • National Institute of Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust, Manchester, UNITED KINGDOM

  • Rheumatology Department, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UNITED KINGDOM

  • Rheumatology Immunology, Hepatology and Dermatology Franchise, Novartis Pharmaceuticals UK Ltd., Camberley, UNITED KINGDOM

  • Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved